LEXINGTON, Ky., Oct. 24 /PRNewswire/ -- Intranasal Therapeutics, Inc. (ITI) today announced that a patent application has been filed for a novel synthetic THC (delta-9-tetrahydrocannabinol) nasal spray product to which ITI holds exclusive worldwide licensing rights.
ITI is developing the THC nasal spray for resistant chemotherapy-induced nausea and vomiting in cancer patients and as an appetite stimulant for anorexia in AIDS patients. The product may have wider therapeutic potential for treating neurological disorders, glaucoma and pain.
An FDA-approved oral, synthetic version of THC currently is on the market as an antiemetic agent for chemotherapy and appetite stimulation for AIDS patients. The THC nasal spray ITI is developing may have advantages over both oral and inhaled THC products, including faster onset of action and relief, and more accurate dosing and bioavailability to improve therapeutic outcomes. Moreover, ITI’s unit dose delivery system helps control intake and limits abuse potential.
The THC nasal spray was invented by Daniel Wermeling, Pharm.D., a faculty member of the University of Kentucky (UK) College of Pharmacy who also is ITI’s Chief Scientific Officer. UK filed the THC product patent application last month. Under an agreement with UK, ITI holds exclusive rights to market the THC product worldwide.
Since its inception, ITI has worked closely with UK’s College of Pharmacy to develop new nasal products and delivery systems. The College is one of the leading pharmacy schools in the United States and a pioneer in the field of nasal drug delivery research. At this time, all of ITI’s nasal spray products and one delivery device are licensed from UK.
Intranasal Therapeutics, Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative nasally delivered pharmaceutical products, with a particular focus on drugs to treat pain and central nervous system disorders for which there is proven, unsatisfied consumer need. The Company currently has four products in its clinical development pipeline, with several others in formulation or preclinical development. ITI’s goal is to become a leader in the field of intranasal pharmaceuticals by applying formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals.
Contact John C. Carlisle President and CEO Intranasal Therapeutics, Inc. Tel.: 859-252-5080 Ext. 226 Fax: 859-252-7280 jcarlisle@intranasal.comhttp://www.intranasal.com
Intranasal Therapeutics, Inc.
CONTACT: John C. Carlisle, President and CEO of Intranasal Therapeutics,Inc., +1-859-252-5080 Ext. 226, or Fax +1-859-252-7280, orjcarlisle@intranasal.com
Web site: http://www.intranasal.com//